240 related articles for article (PubMed ID: 25243340)
1. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
Leaker BR; Barnes PJ; Jones CR; Tutuncu A; Singh D
Br J Clin Pharmacol; 2015 Mar; 79(3):492-500. PubMed ID: 25243340
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
3. Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.
Kerwin EM; Donohue JF; Ferguson GT; Ganapathy V; Ozol-Godfrey A; Rajagopalan K
J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):24-33. PubMed ID: 30457433
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
Ohar J; Tosiello R; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
[TBL] [Abstract][Full Text] [Related]
6. Dose selection for glycopyrrolate/eFlow
Donohue JF; Goodin T; Tosiello R; Wheeler A
Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
8. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
[TBL] [Abstract][Full Text] [Related]
9. Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study.
Singh D; Ravi A; Reid F; Buck H; O'Connor G; Down G
Pulm Pharmacol Ther; 2016 Apr; 37():9-14. PubMed ID: 26827913
[TBL] [Abstract][Full Text] [Related]
10. Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease.
Pleasants RA
Ann Pharmacother; 2019 Mar; 53(3):285-293. PubMed ID: 30175596
[TBL] [Abstract][Full Text] [Related]
11. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.
Rennard S; Fogarty C; Reisner C; Fernandez C; Fischer T; Golden M; Rose ES; Darken P; Tardie G; Orevillo C
BMC Pulm Med; 2014 Jul; 14():118. PubMed ID: 25027304
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Leaker BR; Singh D; Nicholson GC; Hezelova B; Goodin T; Ozol-Godfrey A; Galluppi G; Barnes PJ
Respir Res; 2019 Jun; 20(1):132. PubMed ID: 31253162
[TBL] [Abstract][Full Text] [Related]
18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
19. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
[TBL] [Abstract][Full Text] [Related]
20. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]